Neurotoxicity of high-dose methotrexate in the treatment of non-Hodgkin’s lymphomas in children: clinical and genetic aspects

Neurotoxicity of high-dose methotrexate in the treatment of non-Hodgkin’s lymphomas in children: clinical and genetic aspects

Backround. Treatment protocols for non-Hodgkin’s lymphomas in pediatric patients include a combination of cytotoxic drugs, with methotrexate (MTX) playing a central role, often administered in high doses (1000–5000 mg/m2). MTX is associated with a wide range of side effects, manifesting as organ tox...

Full description

Saved in:
Bibliographic Details
Main Authors: Z. K. Simavonyan, T. T. Valiev, A. L. Kashanina, V. V. Semenova, A. R. Zheleznyak, L. Serdan Ramos, A. Yu. Ikonnikova, T. V. Nasedkina
Format: Article
Language:Russian
Published: ABV-press 2025-05-01
Series:Онкогематология
Subjects:
methotrexate
pharmacogenetic testing
neurotoxicity
<i>mthfr</i>
<i>slc19a1</i>
lymphoma
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/1037
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items